After SNVs validation (stage 2), we observed that CREB1 GA or AA genotype and allele “A” were more common in CM patients than in controls, and that individuals with referred genotypes and allele were under 1.79 and 1.47-fold increased risks of CM than others, respectively. Here, CREB1 is linked to cutaneous mastocytosis.